Impact of Tocilizumab (Anti-IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients with Chronic Antibody-Mediated Rejection.
Chronic antibody-mediated rejection (cABMR) results in the majority of renal allograft losses. Currently, there are no approved therapies. We recently reported on clinical use of tocilizumab (TCZ) for treatment of cABMR in HLA-sensitized kidney transplant patients. IgG1 and IgG3 subclasses of IgG are potent effectors of complement- and antibody-dependent cell-mediated cytotoxicity (ADCC) which are critical mediators of ABMR. Here, we examined the impact of TCZ treatment for cABMR on total IgG, IgG1-4 subclasses and anti-HLA-IgG (total & subclasses). Archived plasma obtained pre- & post-TCZ treatment (8mg/kg, 6x, monthly) from 12 cABMR patients who failed standard of care treatment with IVIg+rituximab with or without plasma exchange were tested for total IgG and IgG1-4 by ELISA, anti-HLA-total IgG, IgG3 and IgG4, and donor-specific antibody (DSA) by luminex assay. Archived plasma from 14 cABMR patients treated with the standard of care were included as controls. Total IgG and IgG1-3 were significantly reduced post-TCZ, while no reduction was seen post-treatment in the control group. Of 11 patients, 8 (73%) showed reduction of anti-HLA-total IgG and IgG3 post-TCZ, but this was not statistically significant. TCZ reduced total IgG and IgG1-3, and anti-HLA-total IgG and IgG3 levels, suggesting that TCZ suppresses Ig production in B cells non-specifically, likely through inhibition of IL-6-mediated signaling to B cells and plasma cells. This may be a contributing factor for the beneficial effect of TCZ on cABMR observed in this patient population.